Table 1 Baseline characteristics of patients in curcumin group and placebo group
Variable | Curcumin group | Placebo group | P value |
|---|---|---|---|
Sex (%) | |||
Male | 61.6 | 39.1 | 0.2 |
Female | 38.4 | 60.9 | |
Smoking (%) | 19 | 13 | 0.4 |
Age (years) | 58 ± 8 | 60 ± 7 | 0.09 |
Duration of diabetes (years) | 8 ± 4.6 | 8 ± 7.9 | 0.7 |
Anti-hyperglycemic drugs metformin | 52% | 43% | 0.8 |
Gelibenclamide | 52% | 43% | |
Gelibenclamide + metformin | 33% | 35% | |
Non | 10% | 17% | |
Anti-hyperlipidemic drugs | 47.6% | 52.2% | 0.6 |
Anti-hypertensive drugs | 66.7% | 65.2% | 0.5 |